Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection.
Liver-related mortality is an increasing problem in human immunodeficiency virus (HIV)/hepatitis B virus (HBV)-coinfected patients receiving highly active antiretroviral therapy (HAART). In HIV-negative patients, HBV chronicity is associated with a reduction in specific T cell responses that can be partially restored by treatment with lamivudine. We studied 5 HIV/HBV-coinfected patients treated with HAART, either with or without addition of a drug with specific anti-HBV activity. Our data show that reconstitution of some HBV-specific T cell responses can also occur in HIV-positive patients after a reduction in HBV load. This potential to recover T cell responses, which has been thought to be critical for HBV control, provides support for the addition of anti-HBV therapy in the treatment of HIV/HBV-coinfected patients.
Lascar
R Monica
RM
Department of Sexually Transmitted Diseases, University College London, United Kingdom.
Gilson
Richard J
RJ
Lopes
A Ross
AR
Bertoletti
Antonio
A
Maini
Mala K
MK
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016516:CD4-CD8 Ratio; D006679:HIV Seropositivity / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000302:isolation & purification*; D006509:Hepatitis B / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D006515:Hepatitis B virus / Q000302:isolation & purification*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D013045:Species Specificity; D013601:T-Lymphocytes / Q000276:immunology*; D019562:Viral Load
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D019259:Lamivudine